Every earnings call for SOLARA — management tone, guidance, KPIs and promise tracking, quarter by quarter.
SOLARA · 5 transcripts · Healthcare · latest Q4 FY26Solara Active Pharma Sciences Limited has 5 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue ₹392 cr; EBITDA ₹61 cr; EBITDA Margin 16%. Revenue of ₹392 crores, up 12% QoQ.
Read full transcript & analysisRevenue ₹346 cr (+15% YoY); EBITDA ₹37 cr; Gross Margin 47%. Non-ibuprofen growth API business achieved 56% gross margin and 25% EBITDA.
Read full transcript & analysisRevenue ₹314 cr; EBITDA ₹35 cr; EBITDA Margin 11%. Revenue declined marginally Q-o-Q to INR314 crores.
Read full transcript & analysisRevenue ₹320 cr; EBITDA ₹57 cr (+36% YoY); PAT 105 million. Revenue grew 15% QoQ to ₹320 crores.
Read full transcript & analysisRevenue ₹320 cr; EBITDA ₹57 cr (+36% YoY); EBITDA Margin 18%. Revenue grew 15% QoQ to ₹320 crores.
Read full transcript & analysis